Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Liabilities (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Total Liabilities for 6 consecutive years, with $57.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 20.83% to $57.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.2 million through Dec 2025, up 20.83% year-over-year, with the annual reading at $57.2 million for FY2025, 20.83% up from the prior year.
  • Total Liabilities hit $57.2 million in Q4 2025 for Insight Molecular Diagnostics, up from $53.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $94.3 million in Q4 2021 to a low of $22.7 million in Q1 2021.
  • Historically, Total Liabilities has averaged $58.0 million across 5 years, with a median of $53.6 million in 2024.
  • Biggest five-year swings in Total Liabilities: surged 330.1% in 2021 and later tumbled 55.95% in 2023.
  • Year by year, Total Liabilities stood at $94.3 million in 2021, then plummeted by 35.88% to $60.5 million in 2022, then dropped by 18.51% to $49.3 million in 2023, then dropped by 3.94% to $47.4 million in 2024, then grew by 20.83% to $57.2 million in 2025.
  • Business Quant data shows Total Liabilities for IMDX at $57.2 million in Q4 2025, $53.1 million in Q3 2025, and $49.4 million in Q2 2025.